← Leaderboards
Alan S Cross
University Of Maryland Baltimore
$8,087,029
Attributed
$8,299,466
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $809.5K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$8,299,466 · 10
By mechanism
R01$5,116,477 · 4
R21$1,646,988 · 4
U54$1,536,001 · 2
Top collaborators
- Robert K Ernst2 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Marcela F Pasetti$26,884,335
- Christopher V. Plowe$27,953,996
- Myron Max Levine$22,681,817
- Karen L. Kotloff$76,457,208
- James B Kaper$25,841,976
Others in their field
Top investigators on “Lipopolysaccharides”
- Bruce A Beutler · Ut Southwestern Medical Center$21,787,231
- Michael Stephen Trent · University Of Georgia$19,970,261
- Daniel E Kahne · Harvard University$19,426,946
- Robert O'Conner · Alion Science And Technology Corp$14,945,723
- Laura E. Nagy · Case Western Reserve University$14,567,506
- Stefanie N. Vogel · University Of Maryland Baltimore$13,942,871
Research focus
LipopolysaccharidesBaseImmune ResponseEndotoxinsInfectionCytokineProductionLeadSurfaceMediatingCellsResponseNeutrophilHost DefenseToll-Like ReceptorsLigandsStimulusSignal TransductionAntigensPeptidesBinding (Molecular Function)Toll-Like Receptor 4ProteinsClinical Research
Grant awards (28)
Novel Vaccine For Multidrug-Resistant Gram-negative Bacterial Infections$193,125
R21 · FY2019 · AI · contact PI
Novel Vaccine For Multidrug-Resistant Gram-negative Bacterial Infections$231,750
R21 · FY2018 · AI · contact PI
Development of a prototype Klebsiella O polysaccharide conjugate vaccine$191,875
R21 · FY2016 · AI · contact PI
Development of a prototype Klebsiella O polysaccharide conjugate vaccine$230,250
R21 · FY2015 · AI · contact PI
Novel peptide antagonist theraphy for superantigen- induced lethal shock$225,577
U54 · FY2013 · AI · contact PI
Novel peptide antagonist theraphy for superantigen- induced lethal shock$245,811
U54 · FY2012 · AI · contact PI
Novel peptide antagonist theraphy for superantigen- induced lethal shock$236,219
U54 · FY2011 · AI · contact PI
Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury$468,212
R01 · FY2010 · HL · contact PI
Novel peptide antagonist theraphy for superantigen- induced lethal shock$242,560
U54 · FY2010 · AI · contact PI
Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury$467,011
R01 · FY2009 · HL · contact PI
Novel peptide antagonist theraphy for superantigen- induced lethal shock$232,637
U54 · FY2009 · AI · contact PI
Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury$456,320
R01 · FY2008 · HL · contact PI
Tularemia$353,197
U54 · FY2008 · AI · contact PI
Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury$428,690
R01 · FY2007 · HL · contact PI
Evaluation of Anti-endotoxin Vaccine for Human Use$395,083
R01 · FY2006 · AI · contact PI
Early events during infection with anthrax$181,264
R21 · FY2006 · AI · contact PI
Evaluation of Anti-endotoxin Vaccine for Human Use$386,830
R01 · FY2005 · AI
Early events during infection with anthrax$220,325
R21 · FY2005 · AI
Evaluation of Anti-endotoxin Vaccine for Human Use$332,012
R01 · FY2004 · AI
Evaluation of Anti-endotoxin Vaccine for Human Use$191,351
R01 · FY2003 · AI
Evaluation of Anti-endotoxin Vaccine for Human Use$398,399
R21 · FY2002 · AI
SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESIS$257,422
R01 · FY2002 · AI
INTERFERON Y MEDIATES ANTI E COLI DEFENSES AND SEPSIS$319,928
R01 · FY2001 · AI
EVALUATION OF ANTIENDOTOXIN VACCINE FOR HUMAN USE$306,697
R01 · FY2001 · AI
SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESIS$252,462
R01 · FY2001 · AI
INTERFERON Y MEDIATES ANTI E COLI DEFENSES AND SEPSIS$309,115
R01 · FY2000 · AI
EVALUATION OF ANTIENDOTOXIN VACCINE FOR HUMAN USE$299,450
R01 · FY2000 · AI
SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESIS$245,894
R01 · FY2000 · AI